Evotec
Nizar Serhan is a seasoned researcher specializing in preclinical in vivo pharmacology, currently serving as Team Leader and Research Scientist at Evotec since January 2020, where responsibilities include project management, study design, and team supervision. Prior to this role, Nizar held post-doctoral research positions at Inserm from December 2017 to December 2019, focusing on the targeting of pancreatic cancer cells using magnetic nanoparticles and HSP70 inhibitors, and from July 2013 to July 2017, investigating the anticancer effects of Oxysterol and Dendrogenin A on acute myeloid leukemia. Nizar began the academic journey as a Ph.D. student at Inserm from September 2009 to March 2013, studying the role of the P2Y13 receptor in cholesterol transport and its implications for atherosclerosis. Academic qualifications include a Ph.D. in Cardiovascular Physiopathology from Université Paul Sabatier Toulouse III and a Master's degree in Human Nutrition from Université Bordeaux.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.